Document resource
Last 28 March 2025, the European Commission decided not to renew the conditional marketing authorisation for Translarna (ataluren) in Duchenne’s disease due to lack of efficacy after 11 years in the market.
Annotated abstract
Ataluren for Duchenne: how politics and social pressure undermined evidence-based decisions
ebmed · 2025-12-13 · canonical JSON source